Brief: Cognition Therapeutics Presents Preclinical Data on Alzheimer’S And Parkinson’S Diseases
15/11/2023 14:22
Nov 15 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS PRESENTS PRECLINICAL DATA
IDENTIFYING
PATHWAYS IMPACTED BY SIGMA-2 RECEPTOR MODULATORS IN ALZHEIMER’S
AND PARKINSON’S DISEASES
Source text for Eikon: ID:nGNX4zGVfD
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB